Bristol Myers Squibb chose the Leiden Bio Science Park as the
European location for a new CAR T cell therapy facility. With this new
facility, we are investing in the expansion of our global network to
bring cell therapy closer to patients with blood cancers in Europe.
production centre is our first European site where we plant our BMS flag and will be our fifth
facility worldwide working on the development of cell therapy. The
facility will be equipped with the latest technology and manufacturing
equipment. The construction work has started in autumn 2021 and the site is expected to
be completed and operational by the end of 2024.
With this new
production centre, we are contributing to the growing role of the
Netherlands as an international leader in the field of CAR T cell